Literature DB >> 313808

An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand's disease and fetal plasma and serum.

I R Peake, A L Bloom, J C Giddings, C A Ludlam.   

Abstract

An immunoradiometric assay (IRMA) has been developed based on the inhibitor which arose in a polytransfused severe haemophiliac. The two-site IRMA measures antigens closely associated with the procoagulant parts of the factor VIII complex, which are termed FVIIC antigens or FVIIICAG. FVIIICAG was present in normal plasma and also, at a slightly lower concentration, in normal serum. In 37 patients with haemophilia A, 36 had FVIIICAG levels of less than 10% of the normal plasma pool. In patients with von Willebrand's disease the levels of FVIIIC and FVIIICAG were in good agreement, both before and after treatment with cryoprecipitate or DDAVP. FVIIICAG was relatively stable in plasma at 37 degrees C and could also be detected in cord and fetal serum. The assay is of potential value for detecting reduced levels of factor VIII, for carrier detection and for the prenatal diagnosis of haemophilia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 313808     DOI: 10.1111/j.1365-2141.1979.tb01131.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Recent advances in haematology.

Authors:  D Samson; I Chanarin; C D Reid
Journal:  Postgrad Med J       Date:  1981-03       Impact factor: 2.401

2.  Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site.

Authors:  Keiji Nogami; Qian Zhou; Hironao Wakabayashi; Philip J Fay
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

3.  Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.

Authors:  M Weinstein; L Chute; D Deykin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

4.  Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine).

Authors:  M Arai; H Inaba; M Higuchi; S E Antonarakis; H H Kazazian; M Fujimaki; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease.

Authors:  H Fukui; M Nishino; S Terada; T Nishikubo; A Yoshioka; S Kinoshita; K Niinomi; K Yoshioka
Journal:  Blut       Date:  1988-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.